共 7 条
- [1] Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma[J]. BLOOD, 2009, 114 (13) : 2721 - 2729Dornan, DavidBennett, FionaChen, YvonneDennis, MarkEaton, DanElkins, KristiFrench, DorothyGo, Mary Ann T.Jack, AndrewJunutula, Jagath R.Koeppen, HartmutLau, JeffreyMcBride, JacquelineRawstron, AndyShi, XiaoyanYu, NancyYu, Shang-FanYue, PengZheng, BingEbens, AllenPolson, Andrew G.
- [2] Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study[J]. LANCET HAEMATOLOGY, 2018, 5 (12): : E609 - E617Dunleavy, KieronFanale, Michelle A.Abramson, Jeremy S.Noy, ArielaCaimi, Paolo FabrizioPittaluga, StefaniaParekh, SamirLacasce, AnnHayslip, John W.Jagadeesh, DeepaNagpal, SunilLechowicz, Mary JoGaur, RakeshLucas, AndreaMelani, ChristopherRoschewski, MarkSteinberg, Seth M.Jaffe, Elaine S.Kahl, BradFriedberg, Jonathan W.Little, Richard F.Bartlett, Nancy L.Wilson, Wyndham H.
- [3] Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial[J]. LANCET, 2011, 378 (9806) : 1858 - 1867Recher, ChristianCoiffier, BertrandHaioun, CorinneMolina, Thierry JoFerme, ChristopheCasasnovas, OlivierThieblemont, CatherineBosly, AndreLaurent, GuyMorschhauser, FranckGhesquieres, HerveJardin, FabriceBologna, SergeFruchart, ChristopheCorront, BernadetteGabarre, JeanBonnet, ChristopheJanvier, MaudCanioni, DanielleJais, Jean-PhilippeSalles, GillesTilly, Herve
- [4] A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA[J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)Sehn, Laurie H.Martelli, MaurizioTrneny, MarekLiu, WenxinBolen, Christopher R.Knapp, AndreaSahin, DenizSellam, GilaVitolo, Umberto
- [5] Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (02) : 155 - +Sehn, Laurie H.Herrera, Alex F.Flowers, Christopher R.Kamdar, Manali K.McMillan, AndrewHertzberg, MarkAssouline, SaritKim, Tae MinKim, Won SeogOzcan, MuhitHirata, JamiePenuel, EliciaPaulson, Joseph N.Cheng, JiKu, GraceMatasar, Matthew J.
- [6] Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (04) : 351 - 363Tilly, HerveMorschhauser, FranckSehn, Laurie H.Friedberg, Jonathan W.Trneny, M.Sharman, Jeff P.Herbaux, CharlesBurke, John M.Matasar, MatthewRai, ShinyaIzutsu, KojiMehta-Shah, NehaOberic, LucieChauchet, AdrienJurczak, WojciechSong, YuqinGreil, RichardMykhalska, LarysaBergua-Burgues, Juan M.Cheung, Matthew C.Pinto, AntonioShin, Ho-JinHapgood, GregMunhoz, EduardoAbrisqueta, PauGau, Jyh-PyngHirata, JamieJiang, YanwenYan, MarkLee, CalvinFlowers, Christopher R.Salles, Gilles
- [7] Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study[J]. LANCET ONCOLOGY, 2019, 20 (07) : 998 - 1010Tilly, HerveMorschhauser, FranckBartlett, Nancy L.Mehta, AmitkumarSalles, GillesHaioun, CorinneMunoz, JavierChen, Andy I.Kolibaba, KathrynLu, DanYan, MarkPenuel, EliciaHirata, JamieLee, CalvinSharman, Jeff P.